A Phase 2, Open-label, Randomized Controlled Trial of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer
Latest Information Update: 16 Jun 2025
At a glance
- Drugs BMS 986218 (Primary) ; Docetaxel (Primary) ; Nivolumab (Primary)
- Indications Carcinoma; Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Bristol-Myers Squibb
Most Recent Events
- 10 Jun 2025 Status changed to discontinued as the business objectives have changed
- 08 Jun 2024 This study has been Completed in Greece, According to European Clinical Trials Database record.
- 07 Dec 2023 Status changed from recruiting to completed.